First-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic lymphocytic leukemia (CLL) whether or not their cancer harbored high-risk genetic features typically associated with poor outcomes, according to results recently published in Clinical Cancer Research.
from Medical Xpress - latest medical and health news stories https://ift.tt/XFNPchY
